| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1040-8428(01)00126-3 |
| P698 | PubMed publication ID | 11418306 |
| P2093 | author name string | Gariépy J | |
| P2860 | cites work | Evidence that glutamic acid 167 is an active-site residue of Shiga-like toxin I | Q24651553 |
| Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands | Q27621547 | ||
| Crystal structure of the holotoxino from Shigella dysenteriae at 2.5 Å resolution | Q27729840 | ||
| Structure of the shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3 | Q27748877 | ||
| Probing the surface of eukaryotic cells using combinatorial toxin libraries | Q30699689 | ||
| Role of bacterial cytotoxins in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura | Q33494674 | ||
| Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. | Q34049372 | ||
| AB5 toxins | Q34303099 | ||
| Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases | Q35772225 | ||
| Protein toxins with intracellular targets | Q36590297 | ||
| Infection by verocytotoxin-producing Escherichia coli | Q36634680 | ||
| Structure-function analyses of Shiga toxin and the Shiga-like toxins | Q37947130 | ||
| Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide | Q38350915 | ||
| The epidemiologic, clinical, and microbiologic features of hemorrhagic colitis | Q39683467 | ||
| Importance of glycolipid synthesis for butyric acid-induced sensitization to shiga toxin and intracellular sorting of toxin in A431 cells. | Q40242899 | ||
| Surfing on a retrograde wave: how does Shiga toxin reach the endoplasmic reticulum? | Q40847412 | ||
| Retroviral transfection of Madin-Darby canine kidney cells with human MDR1 results in a major increase in globotriaosylceramide and 10(5)- to 10(6)-fold increased cell sensitivity to verocytotoxin. Role of p-glycoprotein in glycolipid synthesis | Q40897842 | ||
| The identification of three biologically relevant globotriaosyl ceramide receptor binding sites on the Verotoxin 1 B subunit | Q40949783 | ||
| Autologous stem cell transplants in lymphomas. | Q41056685 | ||
| Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1. | Q41575546 | ||
| Accumulating evidence suggests that several AB-toxins subvert the endoplasmic reticulum-associated protein degradation pathway to enter target cells | Q41614148 | ||
| Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma | Q41656230 | ||
| Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. | Q41903590 | ||
| Mutations affecting the activity of the Shiga-like toxin I A-chain | Q44645523 | ||
| Furin-induced cleavage and activation of Shiga toxin | Q49165095 | ||
| Insertion and orientation of a synthetic peptide representing the C-terminus of the A1 domain of Shiga toxin into phospholipid membranes. | Q50537524 | ||
| Expression of Burkitt lymphoma-associated antigen (defined by the monoclonal antibody 38.13) on both normal and malignant germinal-centre B cells. | Q52264666 | ||
| Differential regulation of glycosphingolipid biosynthesis in phenotypically distinct Burkitt's lymphoma cell lines | Q56917416 | ||
| CD77: an antigen of germinal center B cells entering apoptosis | Q56917430 | ||
| Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum | Q59097697 | ||
| High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America | Q60962262 | ||
| Changes in glycolipid expression in human testicular tumor | Q67660946 | ||
| Monoclonal antibodies against Galα 1 −4Galß 1 −4Glc(Pk, CD77) produced with a synthetic glycoconjugate as immunogen: Reactivity with carbohydrates, with fresh frozen human tissues and hematopoietic tumors | Q67926556 | ||
| Neutral glycosphingolipid expression in B-cell neoplasms | Q68071248 | ||
| Autologous bone marrow transplantation | Q69505801 | ||
| Neutral glycosphingolipids of the globo-series characterize activation stages corresponding to germinal center B cells | Q70248806 | ||
| Autologous bone marrow transplantation | Q70622195 | ||
| A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome | Q71123629 | ||
| Role of processing and intracellular transport for optimal toxicity of Shiga toxin and toxin mutants | Q72210047 | ||
| Where do we stand with respect to the use of peripheral blood progenitor cells? | Q72528083 | ||
| Inhibition of Shiga-like toxins by brefeldin A | Q72592809 | ||
| Ricin A chain utilises the endoplasmic reticulum-associated protein degradation pathway to enter the cytosol of yeast | Q73047414 | ||
| Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells | Q73248328 | ||
| The RNA-N-glycosidase activity of Shiga-like toxin I: kinetic parameters of the native and activated toxin | Q73952496 | ||
| Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation | Q74372881 | ||
| P433 | issue | 1-2 | |
| P304 | page(s) | 99-106 | |
| P577 | publication date | 2001-07-01 | |
| P1433 | published in | Critical Reviews in Oncology Hematology | Q15724423 |
| P1476 | title | The use of Shiga-like toxin 1 in cancer therapy | |
| P478 | volume | 39 |
| Q36609660 | Advance in photosensitizers and light delivery for photodynamic therapy |
| Q57117659 | Biochemical, pathological and oncological relevance of Gb3Cer receptor |
| Q33630801 | Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells |
| Q33412880 | Expression of verotoxin-1 receptor Gb3 in breast cancer tissue and verotoxin-1 signal transduction to apoptosis |
| Q36545508 | Frizzled-7 promoter is highly active in tumors and promoter-driven Shiga-like toxin I inhibits hepatocellular carcinoma growth |
| Q46531930 | Intracellular trafficking of Shiga-toxin-B-subunit-functionalized spherulites |
| Q43843481 | Key role of receptor density in colloid/cell specific interaction: a quantitative biomimetic study on giant vesicles |
| Q40609398 | Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis |
| Q36971525 | Scorpion peptides: potential use for new drug development |
| Q39190558 | Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on raji cells |
| Q37665298 | Subcellular targeting strategies for drug design and delivery |
| Q38022246 | The interactions of human neutrophils with shiga toxins and related plant toxins: danger or safety? |
| Q34929060 | The treatment of malignant meningioma with verotoxin |
| Q91975349 | Verotoxin Receptor-Based Pathology and Therapies |
| Q37954271 | Verotoxin-1 treatment or manipulation of its receptor globotriaosylceramide (gb3) for reversal of multidrug resistance to cancer chemotherapy |
Search more.